CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia

T-cell prolymphocytic leukemia (T-PLL) is a poor prognostic disease with very limited options of efficient therapies. Most patients are refractory to chemotherapies and despite high response rates after alemtuzumab, virtually all patients relapse. Therefore, there is an unmet medical need for novel...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Biomark Res
Päätekijät: Cuesta-Mateos, Carlos, Fuentes, Patricia, Schrader, Alexandra, Juárez-Sánchez, Raquel, Loscertales, Javier, Mateu-Albero, Tamara, Vega-Piris, Lorena, Espartero-Santos, Marina, Marcos-Jimenez, Ana, Sánchez-López, Blanca Andrea, Pérez-García, Yaiza, Jungherz, Dennis, Oberbeck, Sebastian, Wahnschaffe, Linus, Kreutzman, Anna, Andersson, Emma I., Mustjoki, Satu, Faber, Edgar, Urzainqui, Ana, Fresno, Manuel, Stamatakis, Kostantino, Alfranca, Arantzazu, Terrón, Fernando, Herling, Marco, Toribio, María Luisa, Muñoz-Calleja, Cecilia
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2020
Aiheet:
Rapid Communication
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7585232/
https://ncbi.nlm.nih.gov/pubmed/33110606
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-020-00234-z
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia